ly2603618 and Hematologic-Neoplasms

ly2603618 has been researched along with Hematologic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for ly2603618 and Hematologic-Neoplasms

Article	Year
Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies. European journal of medicinal chemistry, 2019, Jul-01, Volume: 173 Topics: Checkpoint Kinase 1; Dose-Response Relationship, Drug; Drug Discovery; Hematologic Neoplasms; Humans; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship	2019

Article

Year

Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.

European journal of medicinal chemistry, 2019, Jul-01, Volume: 173

Topics: Checkpoint Kinase 1; Dose-Response Relationship, Drug; Drug Discovery; Hematologic Neoplasms; Humans; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship

2019